主页 > 医学信息 >

【文摘发布】一项前瞻性研究:治疗结肠癌的抗

RESOURCE: Lancet Oncology 2007; 8:387-394

DOI:10.1016/S1470-2045(07)70108-0

TITLE: Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study

AUTHOR : Prof Sabine Tejpar MD a , Prof Hubert Piessevaux MD b, Kathleen Claes MD c, Patricia Piront MD a, Joost GJ Hoenderop PhD d, Prof Chris Verslype MD a and Prof Eric Van Cutsem MD a

ABSTRACT

Background: Preliminary evidence suggests that magnesium wasting occurs in patients who are treated with epidermal-growth-factor receptor (EGFR)-targeting antibodies for colorectal cancer. The mechanism of this side-effect is unknown, and if all or a subset of patients are affected is also unclear. We aimed to assess the incidence, characteristics, and predictive factors of magnesium wasting during treatment with EGFR-targeting antibodies, and to study the pathophysiology of this phenomenon.

Methods:We measured prospectively magnesium concentrations in a cohort of 98 patients with colorectal cancer treated with EGFR-targeting antibodies with or without combined chemotherapy. The primary outcome measure was the slope of the serum magnesium concentrations over time. In 35 patients, 24-h urinary magnesium excretion was measured. In a subset of patients (n=5), an intravenous magnesium load test was done. 16 patients who had chemotherapy alone acted as controls. A clinical protocol was written before initiation of the study, but because this was a non-interventional study, the protocol was not formally registered.

Findings:95 (97%) patients had decreasing serum magnesium concentrations during EGFR-targeting treatment compared with baseline measurements. The mean serum magnesium slope during EGFR-targeting treatment (with or without combined chemotherapy) was significantly lower compared with chemotherapy alone (−0·00157 mmol/L/day, SD 0·00162 [95% CI −0·00191 to −0·00123] vs 0·00014 mmol/L/day, SD −00076 [−0·00026 to 0·00055]; (t test, p < 0·0001). 24-h urine analysis and intravenous magnesium load tests showed a defect in renal magnesium reabsorption.

Interpretation:EGFR-inhibiting antibodies compromised the renal magnesium retention capacity, leading to hypomagnesaemia in most patients. Future studies should address the effects of exposure and target affinity. Our study suggests a pivotal role of the EGFR-signalling pathway in regulating magnesium homoeostasis. 本人已认领该文编译,48小时后若未提交译文,请其他战友自由认领。 RESOURCE: Lancet Oncology 2007; 8:387-394
来源:柳叶刀肿瘤学2007; 8:387-394
DOI:10.1016/S1470-2045(07)70108-0

TITLE: Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study
题目:一项针对大肠癌表皮生长因子受体靶向治疗中镁消耗前瞻性研究
AUTHOR : Prof Sabine Tejpar MD a , Prof Hubert Piessevaux MD b, Kathleen Claes MD c, Patricia Piront MD a, Joost GJ Hoenderop PhD d, Prof Chris Verslype MD a and Prof Eric Van Cutsem MD a

ABSTRACT
摘要
Background: Preliminary evidence suggests that magnesium wasting occurs in patients who are treated with epidermal-growth-factor receptor (EGFR)-targeting antibodies for colorectal cancer. The mechanism of this side-effect is unknown, and if all or a subset of patients are affected is also unclear. We aimed to assess the incidence, characteristics, and predictive factors of magnesium wasting during treatment with EGFR-targeting antibodies, and to study the pathophysiology of this phenomenon.
背景:初步研究显示镁消耗常发生在大肠癌接受表皮生长因子受体(EGFR)靶向治疗的患者。发生这种副作用的机制还不清楚,到底是全部或者部分患者受累还未知。我们的目的是为了评估大肠癌患者接受抗EGFR靶向治疗过程中镁消耗的发生率、特征和预测因子,并研究其病理生理学、
Methods:We measured prospectively magnesium concentrations in a cohort of 98 patients with colorectal cancer treated with EGFR-targeting antibodies with or without combined chemotherapy. The primary outcome measure was the slope of the serum magnesium concentrations over time 编译:
2007年4月17日在柳叶刀肿瘤学杂志发表一项针对大肠癌患者接受表皮生长因子受体(EGFR)靶向治疗镁消耗前瞻性研究结果显示:抗EGFR靶向治疗损害肾脏对镁重吸收能力,导致大部分患者血镁过低;表皮生长因子受体信号途径在调节体内镁平衡发挥着关键作用。
镁消耗常发生在大肠癌接受表皮生长因子受体靶向治疗的患者。发生这种副作用的机制还不清楚,到底是全部或者部分患者受累还未知。在此背景下比利时学者Sabine Tejpar研究评估大肠癌患者接受抗EGFR靶向治疗过程中镁消耗的发生率、特征和预测因子,并研究其病理生理学。

阅读本文的人还阅读:

【drug-news】辉瑞全球停售

我的综述:造血干细胞移

【medical-news】小鼠试验可

有机锡化合物的合成及其

【drug-news】常用降压药治

作者:admin@医学,生命科学    2010-10-04 05:11
医学,生命科学网